Denali Therapeutics, Inc. Stock, NASDAQ:DNLI
161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080
United States of America
Number of Employees: 261
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.